In vitro studies have shown that milk-derived miR-148 increased prostate cancer proliferation by inhibiting cyclin-dependent kinase inhibitor 1B (CDKN1B) and promoted DNA methyltransferase 1 (DNMT1)-dependent epithelial-mesenchymal transition (EMT) [45]. Here, CDKN1B is linked to prostate cancer.